Effects of EpCAM Overexpression on Breast Cancer Cells
Author Information
Author(s): Johanna M Gostner, Dominic Fong, Oliver A Wrulich, Florian Lehne, Marion Zitt, Martin Hermann, Sylvia Krobitsch, Agnieszka Martowicz, Guenther Gastl, Gilbert Spizzo
Primary Institution: Tyrolean Cancer Research Institute
Hypothesis
What are the molecular changes following EpCAM overexpression in breast cancer cell lines?
Conclusion
EpCAM overexpression leads to cell type-dependent modifications of Wnt signaling components in breast cancer cell lines, resulting in marginal functional changes.
Supporting Evidence
- EpCAM is overexpressed in 30-40% of breast cancer cases and correlates with poor prognosis.
- EpCAM overexpression was associated with increased proliferation in Hs578T cells.
- Downregulation of Wnt signaling inhibitors SFRP1 and TCF7L2 was observed after EpCAM overexpression.
- MDA-MB-231EpCAM cells showed nuclear accumulation of β-catenin.
- Hs578TEpCAM cells exhibited enhanced chemosensitivity to Docetaxel.
Takeaway
When a protein called EpCAM is increased in certain breast cancer cells, it can change how those cells behave, but the effects can be different depending on the type of cell.
Methodology
The study involved transfecting breast cancer cell lines with EpCAM and assessing changes in proliferation, Wnt signaling, and gene expression.
Limitations
The functional alterations observed were marginal and may depend on the lack of accessory molecules necessary for EpCAM's full oncogenic potential.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website